Rory Sheehan|Laura Horsfall|André Strydom|David Osborn|Kate Walters|Angela Hassiotis
Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study
University College London|University College London|University College London|University College London|University College London|University College London
objectives measure incidence movement side effects antipsychotic drugs adults intellectual disability compare rates adults without intellectual disability design cohort study using data health improvement network setting uk primary care participants adults intellectual disability prescribed antipsychotic drugs matched control group adults without intellectual disability prescribed antipsychotic drugs outcome measures new records movement side effect including acute dystonias akathisia parkinsonism tardive dyskinaesia neuroleptic malignant syndrome results 9013 adults intellectual disability control cohort 34 242 adults without intellectual disability together contributed 148 709 personyears data overall incidence recorded movement side effects 275 per 10 000 personyears 95 ci 256 296 intellectual disability group 248 per 10 000 personyears 95 ci 237 260 control group incidence recorded movement side effect significantly greater people intellectual disability compared without incidence rate ratio 130 95 ci 118 142 plt0001 adjustment potential confounders parkinsonism akathisia showing greatest difference groups neuroleptic malignant syndrome although occurring infrequently three times common people intellectual disabilityprescribed antipsychotic drugs incidence rate ratio 303 95 ci 126 730 p0013 differences rates movement side effects groups due differences proportions prescribed first secondgeneration antipsychotic drugs conclusions study provides evidence substantiate longheld assumption people intellectual disability susceptible movement side effects antipsychotic drugs assessment movement side effects integral antipsychotic drug monitoring people intellectual disability regular medication review essential ensure optimal prescribing group